scholarly journals Children Vaccination of COVID-19

2021 ◽  
pp. 1-3
Author(s):  
Sadia Choudhury Shimmi ◽  
M Tanveer Hossain Parash
Keyword(s):  
Clinical Trial ◽  
Infectious Diseases ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Severe Illness ◽  
White House ◽  
Number Of Children ◽  
Predominant Variant ◽  
Vaccines For Children

The Delta variant is currently the highly contagious predominant variant of the SARSCoV-2 virus worldwide that causes severe illness more than the previous variants in unvaccinated people (CDC, 2021). At a White House briefing, the National Institute of Allergy and Infectious Diseases director, Anthony Fauci, predicted that there would be an increase in the number of child hospitalisation proportionate to the increased number of children getting infected with the Delta variant (Press briefing White House, 2021). In response to this situation, the FDA (U.S. Food and Drug Administration) approved Pfizer-BioNTech and Moderna vaccines for children aged 12 – 17 years. Vaccines in children aged 5 – 11 years are currently under clinical trial (Sick-Samuels & Messina, 2021).

scholarly journals Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

2020 ◽  
Vol 3 (11) ◽  
pp. e2024406
Author(s):  
Aviv Ladanie ◽  
Andreas M. Schmitt ◽  
Benjamin Speich ◽  
Florian Naudet ◽  
Arnav Agarwal ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Cancer Therapies ◽  
Clinical Trial Evidence ◽  
Trial Evidence

Pomalidomide

Blood ◽  
2013 ◽  
Vol 122 (14) ◽  
pp. 2305-2309 ◽  
Author(s):  
Martha Q. Lacy ◽  
Arleigh R. McCurdy
Keyword(s):  
Clinical Trial ◽  
Multiple Myeloma ◽  
Disease Progression ◽  
Drug Administration ◽  
Second Generation ◽  
Food And Drug Administration ◽  
Clinical Trial Data ◽  
Trial Data ◽  
The Us ◽  
Immunomodulatory Drug

Abstract This spotlight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food and Drug Administration. This drug was approved for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. This review focuses on the clinical trial data that led to approval and provides advice for treating physicians who are now prescribing this drug for patients.

Evaluation of the small-aperture intracorneal inlay: Three-year results from the cohort of the U.S. Food and Drug Administration clinical trial

2018 ◽  
Vol 44 (5) ◽  
pp. 541-556 ◽  
Author(s):  
John A. Vukich ◽  
Daniel S. Durrie ◽  
Jay S. Pepose ◽  
Vance Thompson ◽  
Corina van de Pol ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Small Aperture ◽  
The U.S
Sign in / Sign up

Export Citation Format

Share Document